TG Therapeutics Inc (NASDAQ:TGTX) saw a large decrease in short interest during the month of February. As of February 28th, there was short interest totalling 16,118,224 shares, a decrease of 15.0% from the February 15th total of 18,973,302 shares. Based on an average trading volume of 1,617,817 shares, the days-to-cover ratio is currently 10.0 days. Currently, 41.3% of the company’s shares are short sold.
TG Therapeutics (NASDAQ:TGTX) opened at $16.80 on Wednesday. TG Therapeutics has a 12-month low of $7.25 and a 12-month high of $17.35. The stock has a market capitalization of $1,190.00, a P/E ratio of -8.75 and a beta of 1.40.
TG Therapeutics (NASDAQ:TGTX) last issued its quarterly earnings data on Thursday, March 8th. The biopharmaceutical company reported ($0.46) earnings per share (EPS) for the quarter, meeting the Thomson Reuters’ consensus estimate of ($0.46). TG Therapeutics had a negative return on equity of 137.47% and a negative net margin of 77,945.40%. The business had revenue of $0.04 million during the quarter, compared to analyst estimates of $0.04 million. equities research analysts expect that TG Therapeutics will post -1.69 EPS for the current year.
A number of analysts have recently commented on the company. B. Riley reaffirmed a “buy” rating and issued a $27.00 price target (up from $21.50) on shares of TG Therapeutics in a research note on Friday, March 9th. BidaskClub raised TG Therapeutics from a “hold” rating to a “buy” rating in a research note on Tuesday, March 6th. Zacks Investment Research raised TG Therapeutics from a “sell” rating to a “hold” rating in a research note on Friday, February 16th. ValuEngine raised TG Therapeutics from a “sell” rating to a “hold” rating in a research note on Friday, February 2nd. Finally, HC Wainwright reaffirmed a “buy” rating and issued a $33.00 price target on shares of TG Therapeutics in a research note on Tuesday, January 16th. Two investment analysts have rated the stock with a hold rating and seven have issued a buy rating to the company’s stock. TG Therapeutics has a consensus rating of “Buy” and an average price target of $24.60.
In other news, CFO Sean A. Power sold 32,006 shares of the company’s stock in a transaction dated Tuesday, January 2nd. The stock was sold at an average price of $8.50, for a total value of $272,051.00. Following the completion of the sale, the chief financial officer now directly owns 517,464 shares of the company’s stock, valued at approximately $4,398,444. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Corporate insiders own 16.70% of the company’s stock.
Several institutional investors and hedge funds have recently modified their holdings of TGTX. Nationwide Fund Advisors grew its position in shares of TG Therapeutics by 24.2% in the 2nd quarter. Nationwide Fund Advisors now owns 26,531 shares of the biopharmaceutical company’s stock valued at $267,000 after purchasing an additional 5,167 shares during the period. Northern Trust Corp grew its position in shares of TG Therapeutics by 29.0% in the 2nd quarter. Northern Trust Corp now owns 598,626 shares of the biopharmaceutical company’s stock valued at $6,016,000 after purchasing an additional 134,463 shares during the period. Vanguard Group Inc. grew its position in shares of TG Therapeutics by 14.3% in the 2nd quarter. Vanguard Group Inc. now owns 2,046,427 shares of the biopharmaceutical company’s stock valued at $20,566,000 after purchasing an additional 255,844 shares during the period. Parametric Portfolio Associates LLC grew its position in shares of TG Therapeutics by 7.5% in the 2nd quarter. Parametric Portfolio Associates LLC now owns 85,612 shares of the biopharmaceutical company’s stock valued at $860,000 after purchasing an additional 5,958 shares during the period. Finally, Voya Investment Management LLC grew its position in shares of TG Therapeutics by 40.2% in the 2nd quarter. Voya Investment Management LLC now owns 22,521 shares of the biopharmaceutical company’s stock valued at $226,000 after purchasing an additional 6,463 shares during the period. Institutional investors and hedge funds own 50.63% of the company’s stock.
WARNING: “TG Therapeutics Inc (TGTX) Sees Large Decrease in Short Interest” was first reported by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are accessing this article on another website, it was copied illegally and reposted in violation of United States and international copyright and trademark law. The original version of this article can be viewed at https://www.dispatchtribunal.com/2018/03/14/tg-therapeutics-inc-tgtx-sees-large-decrease-in-short-interest.html.
TG Therapeutics Company Profile
TG Therapeutics, Inc (TG) is a biopharmaceutical company focused on the acquisition, development and commercialization of treatments for B-cell malignancies and autoimmune diseases. As of December 31, 2016, the Company was developing two therapies targeting hematological malignancies. TG-1101 (ublituximab) is a glycoengineered monoclonal antibody that targets a specific epitope on the cluster of differentiation (CD20) antigen found on mature B-lymphocytes.
Receive News & Ratings for TG Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TG Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.